Guest Editorial Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology February 28, 2025Vol.51 No.08By Harpreet Singh
In Brief Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president February 28, 2025Vol.51 No.08
Drugs & Targets FDA accepts review for odronextamab BLA in r/r follicular lymphoma February 28, 2025Vol.51 No.08
Clinical Roundup First FDA-approved robot-assisted microsurgery for head-and-neck cancer performed at Cedars-Sinai February 21, 2025Vol.51 No.07
Drugs & Targets FDA grants priority review to Boehringer’s BI 1810631 for the treatment of HER2-mutant advanced NSCLC February 21, 2025Vol.51 No.07
White House RFK Jr. is confirmed, NCORP stops collecting data on sexual orientation, genderOne month in: Trump’s impact on oncology February 14, 2025Vol.51 No.06By Claire Marie Porter and Jacquelyn Cobb
Drugs & Targets FDA approves Adcetris + lenalidomide + rituximab for r/r large B-cell lymphoma February 14, 2025Vol.51 No.06
